Patients given apalutamide and hormone therapy around surgery may cut their risk of metastasis or death

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...
Newswise

Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death

An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of ...

Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer

Johnson & Johnson (NYSE: JNJ) today announced new results from the Phase 3 PROTEUS substudy that directly compared the investigational use of apalutamide plus androgen deprivation therapy (ADT), given ...
Cancer Network

Apalutamide/ADT Improves EFS vs Surgery Alone in High-Risk Prostate Cancer

Briganti and colleagues concluded that, together with the main PROTEUS study, the substudy supports 1-year perioperative apalutamide plus ADT as a treatment option for patients with high-risk ...

Healthy Living: Laser Surgery of the Prostate

Last month, we talked about enlarged prostate. Now, Dr. Troy M. Sofinowski joined us to talk about what symptoms should men watch for, and when is it time to see a urologist.
한국미디어뉴스통신

전립선비대증 치료 선택지 '유로리프트'…성기능 보존 고려한 최소침습 치료

중·장년 남성에게 전립선비대증은 흔한 질환이지만 치료를 미루는 경우도 적지 않다. 배뇨 불편이 일상생활에 영향을 미치더라도 수술 이후 성기능 변화나 회복 부담을 우려하는 환자가 적지 않기 때문이다. 최근에는 이러한 부담을 ...